IFNA1 and myeloid sarcoma: Given the heterogeneous nature of MS we questioned whether the observed poor yield of response genes upon IFNß treatment of the whole MS cohort could be a reflection of averaging out differences as a consequence of variation in pharmacological responsiveness between the patients.